NCT00429065

Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.

Selection of Young Patients (< 61 Years), With Good Prognosis Diffuse Large B Cell Lymphoma, According to the Immunophenotype (BCL-6 Negative) to be Treated With Chemoimmunotherapy, With R-CHOP. A Pilot Study.

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 30 (planned)
• Sponsor: Instituto Nacional de Cancerologia de Mexico · Academic / Other
• Sex: All
• Age: 15 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether a specific subtype of lymphoma responds optimally to treatment with rituximab and chemotherapy.

Detailed description

Treatment with rituximab and chemotherapy (R-CHOP)is the accepted treatment for young patients with diffuse large B cell Non-Hodgkin's Lymphoma. However not every patient benefits with this expensive therapy. Recent data suggest that patients with BCL-6 negative lymphoma are more sensitive to Rituximab therapy. It is also known that patients with high-intermediate and high IPI risk does not benefit form standard three weekly CHOP chemotherapy. In this study we intend to define a subgroup of patients in whom this therapy will be of maximum benefit. We will prospectively treat a group of patients with the following characteristics: \< 60 years old low and low intermediate IPI risk BCL-6 negative B-cell NHL Treatment regimen: R-CHOP (standard dosis) for 8 cycles

Conditions

• Non-Hodgkin Lymphoma

Interventions

Type	Name	Description
DRUG	Rituximab

Timeline

• Start date: 2007-01-01
• Completion: 2007-01-01
• First posted: 2007-01-31
• Last updated: 2007-01-31

Locations

1 site across 1 country: Mexico